T. Elebring

发表

What is the most important approach in current drug discovery: doing the right things or doing things right?

A. Plowright, A. Gill, T. Elebring, 2012, Drug discovery today.

Different in vitro and in vivo profiles of substituted 3‐aminopropylphosphinate and 3‐aminopropyl(methyl)phosphinate GABAB receptor agonists as inhibitors of transient lower oesophageal sphincter relaxation

L. Blackshaw, J. Jensen, S. Oja, 2012, British journal of pharmacology.

Effects of (2R)‐(3‐amino‐2‐fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice

J. Jensen, B. Olsson, J. Mattsson, 2005, British journal of pharmacology.

Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.

G. Engberg, H. Nissbrandt, T. Elebring, 1991, The Journal of pharmacology and experimental therapeutics.

Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.

Jonas Boström, Jonas Boström, Thomas Elebring, 2007, Bioorganic & medicinal chemistry.

N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.

B. Largent, A. Carlsson, K. Svensson, 1987, Journal of medicinal chemistry.

Asymmetric synthesis of esomeprazole

Hanna Cotton, Thomas Elebring, Magnus Larsson, 2000 .

The orphan receptor GPR55 is a novel cannabinoid receptor

S. Hjorth, P. Greasley, T. Drmota, 2007, British journal of pharmacology.

(R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of Action

Jacobson, J. Dent, A. Page, 2009, Journal of Pharmacology and Experimental Therapeutics.

Identification and characterisation of a novel splice variant of the human CB1 receptor

Niklas Larsson, S. Hjorth, Thierry Groblewski, 2005, FEBS letters.

6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.

J. Nilsson, A. Carlsson, K. Svensson, 1994, Journal of medicinal chemistry.

5-, 6-, 7- and 8-amino-2-(N,N-di-n-propylamino)-1,2,3,4-tetrahydronaphthalenes: centrally acting DA and 5-HT1A agonists

A. Carlsson, K. Svensson, A. Ekman, 1993 .

(S)- and (R)-8-(Di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz(e)indole- 1-carbaldehyde : A New Class of Orally Active 5HT1A-Receptor Agonists.

A. Carlsson, S. Sundell, K. Svensson, 1994 .

(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.

A. Carlsson, S. Sundell, K. Svensson, 1993, Journal of medicinal chemistry.

Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality.

Nidhal Selmi, Jan Kihlberg, Magnus J. Johansson, 2009, Drug discovery today.

Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.

Christer Alstermark, Ola Fjellström, Karolina Nilsson, 2008, Journal of medicinal chemistry.

376 AZD3355, a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxations in the Dog

J. Jensen, J. Mattsson, K. Nilsson, 2008 .

W1789 The New Reflux Inhibitor Azd3355 Has a Low Propensity for Inducing Central Side Effects Due to Its Affinity for the GABA Carrier

L. Blackshaw, J. Jensen, J. Mattsson, 2008 .

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.

Niklas Blomberg, Britt-Marie Swahn, Paul D Leeson, 2011, Bioorganic & medicinal chemistry letters.

What is the most important approach in current drug discovery: doing the right things or doing things right?

A. Plowright, A. Gill, Adrian L Gill, 2012, Drug discovery today.